Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer (Q44117851)

30 November 2017

title

Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer (English)

1 reference

30 November 2017

main subject

myelodysplastic syndrome

1 reference

1 reference

8

1 reference

30 November 2017

9

Vahdat L

1 reference

30 November 2017

Nichols G

1

1 reference

30 November 2017

de Castro K

2

1 reference

30 November 2017

Wei LX

3

1 reference

30 November 2017

Griffin M

4

1 reference

30 November 2017

Lin N

5

1 reference

30 November 2017

Oratzi A

6

1 reference

30 November 2017

Murty VV

7

1 reference

30 November 2017

Hesdorffer C

10

1 reference

30 November 2017

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

16

1 reference

30 November 2017

issue

9

1 reference

30 November 2017

page(s)

1673-1679

1 reference

Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Risk of leukemia after chemotherapy and radiation treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Clonal analysis of haemopoietic cells in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

In vivo effects of recombinant human stem cell factor treatment. A morphologic and immunohistochemical study of bone marrow biopsies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Increase therapy-related leukemia secondary to breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402631

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402631

1 reference

30 November 2017

1 reference